GlassScriptPhysician profile
Nima Naimi
NPI 1740424712
$1,920.11
in general payments reported to CMS, 2019-2025
16 companies · $39.14 in 2025
The $39.14 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.05 · 2020: $151 · 2021: $542 · 2022: $356 · 2023: $249 · 2024: $562 · 2025: $39.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.19 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $474.19 | 2020-2024 | Farxiga, Saphnelo |
| Glaxosmithkline, LLC. | $352.04 | 2021-2023 | Benlysta |
| Vifor Pharma, INC. | $194.60 | 2020-2021 | |
| Akebia Therapeutics INC | $142.43 | 2019-2024 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $127.70 | 2021-2024 | Velphoro |
| Ucb, INC. | $123.62 | 2024 | Nayzilam |
| Otsuka America Pharmaceutical, INC. | $115.24 | 2022-2024 | Jynarque |
| Aurinia Pharma U.S., INC. | $86.10 | 2022-2024 | Lupkynis |
| Novo Nordisk INC | $78.29 | 2023-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.16 | 2024-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $62.38 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.88 | 2021-2023 | |
| Amgen INC. | $19.27 | 2021 | |
| Ardelyx, INC. | $17.73 | 2024 | Ibsrela |
| Cumberland Pharmaceuticals, INC. | $16.37 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $16.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nima Naimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.